What factors could disrupt MRK's EPS growth in 2025?

While Merck KGaA projects up to 8% EPS growth in 2025, several factors could disrupt this trajectory:

1. **Foreign Exchange Fluctuations**: The company warns of a potential impact of foreign exchange effects on net sales and EBITDA, with an estimated range of -1% to 2%. This suggests that currency fluctuations could negatively affect EPS growth, especially if the euro strengthens against other major currencies.
2. **Market Conditions and Sector Performance**: The pharmaceutical sector's performance can be volatile, influenced by market conditions, regulatory changes, and competitive dynamics. Any adverse event or change in market sentiment could affect Merck's EPS growth.

In summary, while Merck KGaA is optimistic about its growth prospects, there are potential risks and uncertainties that could impact EPS growth in 2025.